/EINPresswire.com/ -- NEW YORK, NY--(Marketwired - Sep 27, 2017) - NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company, today announces the publication of an editorial featuring InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), a client of NNW specializing in the development of novel therapeutics leveraging the pharmacological benefits of cannabinoids.

The publication, titled, "Medical Cannabis Companies Leverage Biosynthesis to Boost Drug Development," highlights the potential of new technology poised to revolutionize cannabis-based drug development. 

To view the full publication, visit: https://www.networknewswire.com/medical-cannabis-companies-leverage-biosynthesis-boost-drug-development/

"The challenges of both chemical synthesis and botanical extraction are a thing of the past for InMed Pharmaceuticals, Inc. (CSE: IN) (OTCQB: IMLFF), which has discovered a way to manufacture cannabinoid compounds in quantities and purities (above 95%) suitable for pharmaceutical use, largely eliminating previous concerns.

"InMed's solutions is a biosynthesis process, utilizing the bacterium E. coli, that starts with cannabinoid DNA so compounds identical to those found in nature can be created in a controlled laboratory. Each cannabinoid can be manufactured individually, to strict purity standards, and without the need to separate individual compounds. Applicable to any of the 90+ cannabinoids, the process involves less time and cost, while a controlled environment affords a high level of quality control every step of the way. In fact, biosynthesis is part of the company's key intellectual property.

"InMed recently filed a provisional patent, which will be converted to an international Patent Cooperation Treaty (PCT) application in the coming months. Upon approval, this coverage will provide InMed's E. coli-based expression system commercial protection."

About InMed

InMed is a preclinical stage biopharmaceutical company specializing in the research and development of novel, cannabinoid-based prescription drug therapies utilizing novel drug delivery systems. InMed conducts research, discovery, preclinical, clinical, regulatory, manufacturing and commercial development activities for its product candidates. InMed's proprietary bioinformatics database assessment tool, the biosynthesis manufacturing process and its drug development programs are the fundamental value drivers of the company.

For more information, visit www.inmedpharma.com.

About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today's market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.

For more information please visit https://www.NetworkNewsWire.com

Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company's SEC filings. These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.